Direxion Healthcare Bull 3X

Eli Lilly Acquires Engage Bio to Accelerate Non-Viral Gene Drug Development

Merck and Kailun Bio's Sac-TMT Succeeds in Phase III Endometrial Cancer Trial

CDD and Eli Lilly Collaborate to Integrate TuneLab AI Platform into CDD Vault

Trump Portfolio Precisely Trades UnitedHealth Before Medicare Policy Reversal

Fideuram Intesa Sanpaolo Acquires 84,300 JNJ Shares Worth $17.4M in Q4

Eli Lilly and Company announces an additional $4.5 billion investment in its Indiana manufacturing sites

Eli Lilly and Novo Nordisk are preparing to launch high-dose obesity treatments in the South Korean market

Financial disclosure reveals Donald Trump invested in Eli Lilly in Q1 2026, coinciding with the government's push for favorable weight-loss drug policies.

UnitedHealth Group Faces Profit Pressure Amid Rising Medical Costs and Membership Structure Changes

Eli Lilly Completes Key Drug Interaction Study for its KRAS Inhibitor, Olomorasib

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Canada Approves Generic Version of Novo Nordisk's Ozempic, Potentially an Indirect Positive for Lilly

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Silexion Therapeutics

Micware

GCL Global

MetaVia

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

Merck & Co.'s experimental antibody-drug conjugate, Sac-TMT, developed with Kelun-Biotech, succeeded in a Phase 3 trial for endometrial cancer, showing improved survival rates over chemotherapy. This success follows positive lung cancer trial results. Sac-TMT is part of Merck's strategy to maintain revenue after Keytruda's patent expiration. Analysts predict Sac-TMT could generate $2.6 billion in sales by 2030 and $7.2 billion by 2034.

biopharmadive

Merck

SKB BIO

Gilead Sciences

AstraZeneca

Daiichi Sankyo Company, Limited

ROYAL BANK OF CANADA

AstraZeneca PLC

Daiichi Sankyo

Merck ADC, licensed from China, hits mark in first big global trial

ELIL

SBIO

LABU

LLYX

Engage Biologics Inc. has been acquired by Eli Lilly and Company for up to $202 million to enhance the development of non-viral genetic medicines. Engage's Tethosome platform aims to improve DNA delivery's potency, tolerability, and redosability. The acquisition combines Engage's innovative technology with Lilly's extensive genetic medicine capabilities, promising to accelerate the development of new genetic therapies.

Fidelity

Eli Lilly

VanEck Biotech ETF

Direxion Daily LLY Bull 2X Shares

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Defiance Daily Target 2X Long LLY ETF

SPDR S&P Biotech

Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines

ARKG

ELIS

The 2026 Milliman Medical Index reveals that healthcare costs for an average American family have reached $37,824, marking a 7.9% increase—the highest in over a decade. Key drivers include a 14.8% rise in pharmacy costs, influenced by GLP-1 drugs, and a 7.5% increase in outpatient facility costs. The report highlights the role of AI in optimizing billing processes, contributing to this significant cost growth.

- The Milliman Medical Index for 2026 reveals that healthcare costs for an average American family have reached $37,824, marking a 7.9% increase, the highest in over a decade.  
- Contributing factors include a 14.8% rise in pharmacy costs driven by GLP-1 drugs and high-cost specialty medications, alongside a 7.5% increase in outpatient facility costs.  
- Additionally, the introduction of artificial intelligence in billing processes is noted as a significant new factor in these rising costs.

MorningStar

Novo Nordisk AS

Ark Genomic Revolution ETF

SPDR S&P Health

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Direxion Daily LLY Bear 1X Shares

Defiance Daily Target 2X Long NVO ETF

Health Care Select Sector SPDR

SPDR Pharmac

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VG Health

Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026

PILL

The Supreme Court declined to hear appeals from six drugmakers against Medicare's drug price negotiations. This decision is projected to save patients $1.5 billion and Medicare $6 billion in the first year. Ongoing legal challenges in lower courts may lead to future Supreme Court reviews.

Bristol Myers Squibb

Johnson & Johnson

Direxion Pharma & Medical Bull 3X

Supreme Court rejects drugmakers’ bid to halt Medicare price talks

LABD

LLYZ

Collaborative Drug Discovery (CDD) has partnered with Eli Lilly to integrate Lilly TuneLab, an AI/ML drug discovery platform, into CDD Vault. This collaboration allows biotech companies using CDD Vault to access Lilly's predictive models, enhancing data-driven decision-making in drug discovery. CDD's CEO, Barry A. Bunin, emphasized the importance of collaboration in addressing complex challenges in the field. The integration aims to streamline workflows for scientists and supports CDD's vision of efficient web-based collaboration.

Direxion S&P Biotech Bear 3X

Defiance Daily Target 2X Short LLY ETF

Collaborative Drug Discovery Partners with Lilly TuneLab to Make Lilly AI/ML Models Available in CDD Vault

Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired 84,300 shares of Johnson & Johnson (NYSE: JNJ) valued at approximately $17.4 million in Q4. Other institutional investors also increased their stakes. JNJ shares opened at $229.97, with a 12-month range of $149.04 to $251.71. The company reported Q1 earnings of $2.70 EPS, exceeding estimates, and announced a quarterly dividend of $1.34 per share, up from $1.30.

Market Beat

SPDR S&P Health Equip

iShares US Medical Devices

Bank of NY Mellon

Stifel Financial

Wells Fargo

Goldman Sachs

Barclays

BANK OF NEW YORK MELLON CORP DEP SHS REPG 1/4000TH INT SER K PFD

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

GS Hldg R

Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Johnson & Johnson $JNJ

Donald Trump disclosed stock purchases of up to $680,000 in Eli Lilly as Medicare initiatives advanced GLP-1 drug coverage. The investments coincided with policies benefiting the drugmaker's obesity treatments. Trump's purchases also included shares in West Pharmaceutical Services, valued between $250,000 and $500,000. A spokesperson stated that his investments are managed independently by third-party institutions. Eli Lilly shares rose 2.73% to $1015.09, gaining 9.4% over the past month.

benzinga_article

West Pharmaceutical

Thomson Reuters

S&P 500

Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report

Johnson & Johnson (NYSE: JNJ) is highlighted as a strong investment choice due to its robust business model, AAA credit rating, and a history of 64 consecutive dividend increases. Despite facing legal challenges and potential government price negotiations, the company is expected to grow sales by 7% year-over-year by 2026. Its diversified portfolio and essential products position it well to navigate economic downturns, making it a reliable option for investors seeking stability.

nasdaq

NVIDIA

Intel

S&P Global

NVIDIA Corporation

Meet the Dividend King With a Higher Credit Rating Than the U.S. Government

UNHG

Zacks Research has raised its Q1 2027 earnings estimate for UnitedHealth Group (NYSE:UNH) to $6.87 per share, up from $6.77. The consensus estimate for the full-year earnings is $18.29 per share. Various analysts have given mixed ratings, with an average rating of 'Moderate Buy' and a price target of $381.83. UNH shares opened at $390.44, with a market cap of $354.57 billion.

Unitedhealth

Leverage Shares 2X Long UNH Daily ETF

iShares US Healthcare Providers

Berkshire Hathaway

Berkshire Hathaway B

HSBC

HSBC HOLDINGS

HSBC Holdings Plc

Jefferies Financial

Piper Sandler Cos

UBS Group AG

HSBC 5xShortSG241213

Zacks Research Issues Optimistic Estimate for UNH Earnings

GSA Capital Partners LLP increased its stake in UnitedHealth Group (NYSE:UNH) by 203.2% in Q4, owning 6,673 shares valued at $2.2 million. Other institutional investors also raised their holdings. Analysts have upgraded their ratings, with Barclays setting a price target of $373.00. Despite Berkshire Hathaway's exit affecting sentiment, UnitedHealth's recent earnings showed positive results, maintaining a market cap of $354.57 billion.

KeyCorp

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP

Direxion Healthcare Bull 3X(CURE.US)